Korea S.E.
18:00:00 2024-05-27 EDT
5-day change
1st Jan Change
4,100
KRW
-0.73%
-0.73%
-30.63%
Oxford Vacmedix UK Limited announced that it has received KRW 13.28575 billion in funding from Cancer Rop Co., Ltd.
On March 6, 2018, Oxford Vacmedix UK Limited closed the transaction. The company received KRW 13,285,750,000 in its series A round of funding from new investor Cancer Rop Co., Ltd. (KOSDAQ:A180400) and existing Chinese investors.
Dx&Vx Co-Develops Bio-Healthcare Big Data Platform with LG CNS
12-20
CI
Dx & Vx Co., Ltd. completed the acquisition of Avixgen, Inc. from a group of sellers
23-06-27
CI
Dx & Vx Co., Ltd. announced that it has received KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors
23-06-13
CI
Dx & Vx Co., Ltd. agreed to acquire Avixgen, Inc. from Renaissance Asset Management, Nouveau International Co., Ltd., Lee Mi-ja, Seo Jin - young, Kim Jae-hyun , Cho Il-hyun,Park So -yeon, Jeong Ja -woon, Kim Young- ju, Yang Young-jin, Kim Hye -min and Um In-kyung for KRW 9.2 billion.
23-05-23
CI
DxVx Appoints Kevin Kwon as New President
23-05-16
CI
DxVx Appoints Yong Gu Lee as CEO
23-05-16
CI
Dx & Vx Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-13
CI
Dx & Vx Co., Ltd. announced that it expects to receive KRW 9.223311402 billion in funding from Renaissance Asset Management and other investors.
23-04-06
CI
Dx & Vx Co., Ltd. announced that it has received KRW 17 billion in funding
22-10-05
CI
Dx & Vx Co., Ltd. completed the acquisition of Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok.
22-10-03
CI
Dx & Vx Co., Ltd. agreed to acquire Korea Biopharm Co., Ltd. from Jang, Byung Ha, Heo, Won Jung, Kim, Min E, Jang, So Yeon, Kim, Sung Gon and Hyun, Mi Ok for approximately KRW 15 billion.
22-09-14
CI
Dx & Vx Co., Ltd. announced that it expects to receive KRW 1.78 billion in funding
22-09-06
CI
Cancer Rop Co., Ltd. announced that it expects to receive KRW 20 billion in funding
21-08-29
CI
Cancer Rop Co., Ltd. announced that it has received KRW 999.99252 million in funding
20-06-28
CI
Cancer Rop Co., Ltd. announced that it expects to receive KRW 999.99252 million in funding
20-06-17
CI
D S and partners limited company cancelled the acquisition of 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd..
20-04-28
CI
Cancer Rop Holdings Co., Ltd. cancelled the acquisition of 3.4% stake in Cancer Rop Co., Ltd. from Myungji Global Bio Fund.
19-07-10
CI
Ds&Partners signed a contract to acquire 10.2% stake in GI Innovation, Inc. from Cancer Rop Co., Ltd. for KRW 7.5 billion.
19-04-28
CI
Resort Savers, Inc. Announces Medical Distribution Partnership with South Korea based CancerROP
18-07-16
CI
GI Innovation, Inc. announced that it has received KRW 4.999995 billion in funding from Cancer Rop Co., Ltd.
18-07-12
CI
Cancer Rop Holdings Co., Ltd. singed a contract to acquire 3.4% stake in Cancer Rop Co., Ltd. from Myungji Global Bio Fund for approximately KRW 9.5 billion.
18-07-10
CI
GI Innovation, Inc. announced that it expects to receive KRW 4.999995 billion in funding from Dx & Vx Co., Ltd.
18-06-27
CI
Cancer Rop Co., Ltd. announced that it has received KRW 10 billion in funding
18-04-12
CI
Oxford Vacmedix UK Limited announced that it has received KRW 13.28575 billion in funding from Cancer Rop Co., Ltd.
18-03-05
CI
Oxford Vacmedix UK Limited announced that it expects to receive KRW 10.618366 billion in funding from Cancer Rop Co., Ltd.
18-03-04
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Dx & Vx Co Ltd, formerly Cancer Rop Co Ltd, is a Korea-based company primarily engaged in the molecular diagnosis business. The Molecular Diagnosis Business segment is engaged in the manufacture and sale of deoxyribonucleic acid (DNA) chips, polymerase chain reaction (PCR) chips and other products. manufacture and sale of diagnostic reagents used for molecular diagnosis, and various enzymes and experimental reagents used for biological research.
More about the company
1st Jan change
Capi.
-30.63% 91.19M -36.44% 8.68B -3.29% 3.2B +19.31% 2.71B -18.71% 2.04B -22.03% 1.64B +64.58% 1.43B +34.58% 841M -7.42% 718M -25.51% 538M
Bio Diagnostics & Testing
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
DX & VX CO., LTD. 
